Leerink Partnrs Increases Earnings Estimates for CureVac

CureVac (NASDAQ:CVAC - Free Report) - Investment analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for CureVac in a report released on Tuesday, May 20th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.68) per share for the year, up from their previous estimate of ($0.69). The consensus estimate for CureVac's current full-year earnings is $0.72 per share. Leerink Partnrs also issued estimates for CureVac's Q4 2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.34) EPS.

CureVac (NASDAQ:CVAC - Get Free Report) last released its earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). The firm had revenue of $0.94 million for the quarter, compared to analyst estimates of $4.27 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%.

A number of other analysts also recently weighed in on CVAC. UBS Group decreased their price target on CureVac from $13.00 to $12.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. JMP Securities restated a "market outperform" rating and set a $10.00 target price on shares of CureVac in a research report on Wednesday.

CureVac Trading Up 3.1%

NASDAQ CVAC traded up $0.14 during mid-day trading on Friday, reaching $4.49. 452,554 shares of the stock were exchanged, compared to its average volume of 749,479. The stock has a market cap of $1.01 billion, a P/E ratio of 8.17 and a beta of 2.43. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. CureVac has a one year low of $2.37 and a one year high of $5.28. The stock has a 50 day simple moving average of $3.29 and a 200-day simple moving average of $3.31.

Institutional Investors Weigh In On CureVac

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP acquired a new stake in shares of CureVac in the 1st quarter valued at about $853,000. BNP Paribas Financial Markets bought a new position in CureVac in the fourth quarter worth approximately $585,000. Millennium Management LLC grew its stake in CureVac by 10.3% in the first quarter. Millennium Management LLC now owns 1,816,984 shares of the company's stock valued at $5,033,000 after acquiring an additional 169,947 shares during the period. Two Sigma Investments LP bought a new stake in shares of CureVac during the fourth quarter valued at approximately $391,000. Finally, State of Wyoming bought a new stake in shares of CureVac during the first quarter valued at approximately $317,000. 17.26% of the stock is owned by institutional investors.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.